Isotechnika Completes Patient Recruitment of Pivotal Phase 3 Psoriasis Trial

Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA)
announced today that the Company has completed recruitment of its
pivotal Phase 3 European/Canadian psoriasis trial (ESSENCE). As of
July 20, 2007, the Company closed recruitment at 638 patients. The
patient population is made up of 228 Canadian patients, 294 patients
from Germany and 116 patients from Poland. "We are pleased that
patient recruitment was achieved in the anticipated timeframe,"
stated Dr. Randall Yatscoff, Isotechnika's President & CEO. "The
ability to complete recruitment quickly speaks to the unmet medical
need for a treatment for this serious and debilitating disease. This
is a major milestone in facilitating the advancement of ISA247
towards final marketing approval for the treatment of psoriasis.". A
second pivotal Phase 3 European psoriasis trial including
approximately 360 patients is expected to commence in the first
quarter of 2008. This trial, in conjunction with the ongoing ESSENCE
trial, will provide sufficient patient numbers to file for regulatory
approval in Europe and Canada.

About Isotechnika: Edmonton-based Isotechnika Inc. is an
international biopharmaceutical company focused on the discovery and
development of novel immunosuppressive therapeutics that are designed
to offer advantages ove other currently available treatments while
offering therapeutic choices to clinicians. Isotechnika looks to
become the market leader of drug therapies for indications such as
transplantation of solid organs (with Hoffman La Roche) and treatment
of autoimmune disorders such as uveitis (with Lux Biosciences) and
psoriasis. There is a significant unmet medical need in the treatment
of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential exceeds CDN$2 billion annually in
sales for calcineurin inhibitors such as ISA247. Isotechnika's lead
drug, ISA247, has successfully completed a Phase 3 Canadian trial for
the treatment of moderate to severe psoriasis. ISA247 is currently
being investigated in a Phase 3 European/Canadian psoriasis trial and
a Phase 2b North American trial for the prevention of kidney graft
rejection subsequent to transplantation Isotechnika Inc. is a
publicly traded company on the Toronto Stock Exchange under the
symbol "ISA". More information on Isotechnika can be found at
www.isotechnika.com.

Partnerships with Isotechnika Inc.

Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and commercialize ISA247 for all transplant indications. On
September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use of ISA247 and TAFA93 specifically with drug eluting devices for
the non-systemic treatment of vascular, cardiovascular, target vessel
and tissue disorders Isotechnika Inc. and Cellgate Inc. signed an
option agreement on April 25, 2006, granting Isotechnika the option
to obtain an exclusive license to develop and commercialize
conjugates consisting of Cellgate's patented transporter technology
for the topical delivery of ISA247 in patients suffering from mild to
moderate psoriasis. On May 25, 2006, Isotechnika Inc. signed an
agreement with Lux Biosciences, Inc. of Jersey City, New Jersey
granting Lux Biosciences worldwide rights to develop and
commercialize Isotechnika's lead drug, ISA247 for the treatment and
prophylaxis of all ophthalmic diseases.

Forward-Looking Statements:

This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc., Phone: +1-780-487-1600, 247, Fax: +1-780-484-4105,
ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., Phone: +1-780-909-4661,
Fax: +1-780-484-4105, sgillis-paulgaard@isotechnika.com (ISA.)